Search Results
.M., Composto, R.J., Freeman, T.A., Wickstrom, E., Ducheyne, P., Jungkind, D., Shapiro, I.M., Hickok, N.J.: The inhibition of Staphylococcus epidermidis biofilm formation by vancomycin-modified titanium alloy and implications for the treatment of periprosthetic
53 65 Leclercq, R., Derlot, E., Duval, J., Courvalin, P.: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium . NEngl J Med 319 , 157
species most frequently isolated from clinical samples ( Maasjost et al., 2009 ) and cloacal samples of poultry ( Ünal et al., 2017; Aslantaş, 2019 ). Glycopeptides (such as vancomycin and teicoplanin) are effective antibiotics for the treatment of Gram
increased concern and a major pathogen of hospital-acquired infections [ 1, 2 ]. Vancomycin was considered to be the best alternative for the treatment of multidrug-resistant MRSA. However, there have been increasing reports of vancomycin-resistant S
Hryniewicz, W., Szczypa, K., Bronk, M., Samet, A., Hellmann, A., Trzcinski, K.: First report of vancomycin-resistant Enterococcus faecium isolated in Poland. Clin Microbiol Infect 5 , 503-505 (1999
References 1. Cetinkaya , Y. , Falk , P. , Mayhall , C.G. : Vancomycin-resistant enterococci . Clin Microbiol Rev 13 , 686 – 707 ( 2000
-type vancomycin-resistant enterococci on Norwegian poultry farms three years after avoparcin was banned. J. Appl. Microbiol. 89 , 478–485. Kruse H. Continuing high prevalence of VanA
Linden, P.K., Miller, C.B.: Vancomycin-resistant enterococci: The clinical effect of a common nosocomial pathogen. Diagn Micr Infect Dis 33 , 113–120 (1999). Miller C
Cornely, O. A., Crook, D. W., Esposito, R., et al.: Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis., 2012, 12 , 281
), 421–433. 5 Leclercq, R., Derlot, E., Duval, J., et al.: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med., 1988